Brooks Laboratories Reports Robust Q1 FY26 Results with 265.06 Lakh Net Profit

Brooks Laboratories Limited , a prominent player in the pharmaceutical sector, has announced its unaudited financial results for the first quarter of fiscal year 2026, ending June 30, 2025. The company has demonstrated a remarkable turnaround, posting a significant profit and substantial revenue growth.

Financial Highlights

• Net Profit: Brooks Laboratories reported a net profit of Rs. 265.06 lakhs for Q1 FY26, a stark contrast to the loss of Rs. 21.23 lakhs in the same quarter of the previous year.
• Revenue: The company's revenue from operations surged to Rs. 2,551.19 lakhs, marking a 42.3% increase from Rs. 1,793.29 lakhs in Q1 FY25.
• Total Income: Total income rose to Rs. 2,572.89 lakhs, up from Rs. 1,800.22 lakhs year-over-year.

Consolidated Performance

On a consolidated basis, Brooks Laboratories' performance was even more impressive:

• Consolidated Net Profit: The company posted a significantly higher net profit of Rs. 958.48 lakhs.
• Joint Venture Contribution: A substantial portion of the consolidated profit came from the company's share in its jointly controlled entity, Brooks Steriscience Limited, which contributed Rs. 693.42 lakhs.

Brooks Steriscience Limited Performance

Brooks Steriscience Limited, the jointly controlled entity, reported strong results:

• Revenue: Recorded revenue from operations of Rs. 3,230.70 lakhs.
• Licensing Income: Included a substantial licensing income of Rs. 2,083.56 lakhs.
• Profit: Achieved a profit after tax of Rs. 1,415.14 lakhs for the quarter.

Earnings Per Share

• Basic EPS: Improved to Rs. 0.90 from negative Rs. 0.08 in the previous year's quarter.

Management Commentary

The Board of Directors reviewed and approved these results at their meeting held on August 13, 2025.

Segment Information

Brooks Laboratories operates in one reportable business segment: Pharmaceuticals.

Balance Sheet Highlight

As of the latest reported period, the company's paid-up equity share capital stands at Rs. 2,945.72 lakhs, with a face value of Rs. 10 per share.

The robust financial performance of Brooks Laboratories in Q1 FY26 reflects a strong recovery and growth trajectory for the company. The significant contributions from its joint venture, Brooks Steriscience Limited, particularly in licensing income, have played a crucial role in boosting the consolidated results. As the pharmaceutical sector continues to evolve, Brooks Laboratories appears well-positioned to capitalize on market opportunities and drive further growth.